

Tuberculosis profile: Mozambique

Population 2022: 33 million

Estimates of TB burden*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	119 000 (72 000-177 000)	361 (220-537)
HIV-positive TB incidence	30 000 (18 000-45 000)	92 (56-137)
MDR/RR-TB incidence**	4 300 (2 400-6 200)	13 (7.1-19)
HIV-negative TB mortality	5 300 (2 400-9 300)	16 (7.4-28)
HIV-positive TB mortality	4 300 (2 400-6 800)	13 (7.2-21)

Estimated proportion of TB cases with MDR/RR-TB*, 2022

New cases	2.9% (2.8-3.1)
Previously treated cases	14% (13-16)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2022	92% (62-150)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2022	9% (4-14)

TB case notifications, 2022

Total new and relapse	110 084
- % tested with rapid diagnostics at time of diagnosis	79%
- % with known HIV status	100%
- % pulmonary	97%
- % bacteriologically confirmed ^	43%
- % children aged 0-14 years	12%
- % women (aged ≥15 years)	42%
- % men (aged ≥15 years)	46%
Total cases notified	110 674

TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	27 957	25%
- on antiretroviral therapy	27 368	98%

Drug-resistant TB care**, 2022

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	82%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	82%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	1 251
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	1 383
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	69
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	54
MDR/RR-TB cases tested for resistance to any fluoroquinolone	581

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	94%	96 311
Previously treated cases, excluding relapse, registered in 2021	89%	783
HIV-positive TB cases registered in 2021	91%	23 932
MDR/RR-TB cases started on second-line treatment in 2020	75%	1 315
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020	72%	67


TB preventive treatment, 2022

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	50% (49-51)


Funding for TB

Funding for TB, 2022 (US\$ millions)	28
- % domestic funding	13%
- % international funding	87%
National TB budget, 2023 (US\$ millions)	32
- Funding source, domestic	13%
- Funding source, international	87%
- Unfunded	0%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2022 (Number)



Cases attributable to five risk factors, 2022 (Number)



Funding for TB (US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed

Generated 2024-04-05 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)